BioVie: Taken in chokehold by its majority shareholder (incl. Excel workbook)
As the majority shareholder has taken this company in chokehold, upside for investors is severely limited. This might make the upcoming phase 3 results a dud even if data come in strong.
BioVie BIVI 0.00%↑ is a clinical stage pre-revenue biotech company developing drugs against Alzheimer’s and Parkinson’s. As important phase 3 data are due by the end of this month, there is an opportunity to benefit from increased volatility priced into its option chain. I have attached my Excel workbook with the company’s key financials and the details of my trade.
Fallacy Alarm is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.
BioVie’s lead candidate, called NE3107, acts as an inhibitor for insulin resistance. Insulin plays a crucial role in brain function by regulating sugar uptake into brain cells. BioVie purchased NE3107 and other drug candidates from NeurMedix, a privately held biotech company, on April 27, 2021.
Keep reading with a 7-day free trial
Subscribe to Fallacy Alarm to keep reading this post and get 7 days of free access to the full post archives.